LGZGD is primarily associated with PI3K/Akt, IL-17, TNF, Th17 cell differentiation, HIF-1, and TLR signaling pathways in treating NAFLD. This evidence concerns the gene HIF1A and metabolic dysfunction-associated steatotic liver disease.